摘要
Kiran GODSE 医师
皮肤科医师
Melasma approach in dark skin
Objectives: Melasma is common in dark skin individuals and woods light is often not useful in assessing depth of melasma. Approximately 80% of the Indian population present skin color heterogeneity on the face, irrespective of age and gender.
Introduction: Melasma is a common acquired pigmentary skin disorder characterized by a symmetrical macular pigmentation of sun-exposed areas like the face
The three major patterns of pigmentation in melasma are centrofacial (cheeks, forehead, upper lip, and nose), malar (cheeks and nose), and mandibular (mandibular area of cheeks)
Materials / method: Wood’s lamp examination is done to identify the location of pigment but is limited to epidermal melasma and cannot be used reliably in Fitzpatrick skin types V and VI as dark skin melanin pigmentation obscures the detection of dermal melanin.
Wood's lamp examination (340 to 400nm) highlights the difference in pigmentation of the affected skin. Broad spectrum sun screen with SPF of atleast 30, which covers UVA, UVB and visible light. It should be applied liberally (tea spoon rule) every 2-3 hours. Triple combination containing hydroquinone tretinoin and flucinolone acetonide is still first line
Results: 40 women from India treated with serial peels + modified Kligman’s formula (MKF) vs. MKF alone for 5 months. Peel group showed better response in an Indian study.
Tranexamic acid, an anti-fibrinolytic agent, through inhibition of plasminogen activator pathway in skin, is proposed to act by preventing melanocytes activation due to ultraviolet (UV) light, hormones, and injured keratinocyte. Lasers can be used as an adjuvant therapy in resistant cases, provided the selection of patient and counselling has been done properly.
Conclusion: triple combination with chemical peels is preferred first line therapy in Indian patients.
Lasers need to be used carefully in dark skinned patients.
披露 - Kiran GODSE
> 您是否获得了任何资金来支持您关于这个主题的研究?
不是
> 您在这项研究工作中是否获得过任何酬金、报酬或其他形式的补偿?
不是
> 您是否与任何可能与您研究中涉及的药物、材料或器械存在激烈竞争的实体有任何财务关系?
不是
> 您是否拥有或已申请过与您研究中所讨论的仪器、药物或材料相关的任何专利?
不是
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
Published on 2023年 7月 24日 - Recorded during IMCAS Asia 2023